Pregancies ending in abortion do not increase the risk of developing breast cancer (p 1007)March 24, 2004Results of a major international collaboration investigating the relationship between abortion and breast cancer are published in this week's issue of THE LANCET. Authors of the study conclude that the totality of the worldwide evidence does not suggest any increase in the risk of developing breast cancer for women who have had a pregnancy that ended in miscarriage or induced abortion. The Collaborative Group on Hormonal Factors in Breast Cancer (secretariat based at the University of Oxford, UK) re-analysed data from 53 epidemiological studies undertaken in 16 countries. Data were available from 44000 women who had taken part in studies where any history of abortion had been recorded before-and often many years before-any breast cancer was diagnosed. Results were expressed as the "relative risk" of breast cancer, which compares the chances of developing breast cancer in women with, and without, some such record of abortion; a relative risk of 1.0, or less than 1.0, would indicate no adverse effect on the subsequent risk of breast cancer. In these studies, the averaged relative risk of breast cancer was 0.98 for women who had had a pregnancy that ended as a miscarriage and 0.93 for women who had had a pregnancy that ended as an induced abortion, indicating no increased risk of breast cancer after miscarriage or abortion. The number of abortions was also not associated with any change in breast-cancer risk. Data on 39000 women with breast cancer in potentially less reliable studies (where women were asked after the diagnosis of breast cancer about any previous abortions) gave, on average, misleading results. Professor Richard Peto says "Studies can give misleading results if women are asked about previous abortions only after they are diagnosed with breast cancer. This may well be because, on average, women with breast cancer are more likely than other women to disclose any prior induced abortions." (quote by e-mail, does not appear in published paper). Professor Valerie Beral comments: "The totality of the worldwide epidemiological evidence indicates that pregnancies ended by induced abortion do not have adverse effects on women's subsequent risk of developing breast cancer." Lancet |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. Breast density associated with increased risk of cancer recurrence A new study finds that women treated for breast cancer are at higher risk of cancer recurrence if they have dense breasts. Published in the December 15, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study's results indicate that breast cancer patients with dense breasts may benefit from additional therapies following surgery, such as radiation. Researcher: 'Optical biopsy' for breast cancer increasingly accurate But women may not have to endure the medical costs, stress and potential complications that accompany such invasive biopsies forever. A University of Florida biomedical engineering researcher is making progress on an "optical biopsy" that has the potential to determine whether growths are cancerous without ever puncturing the skin. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||